Chris Simon, the CEO of Haemonetics Corporation, will engage with investors during a fireside chat at Goldman Sachs' healthcare conference on June 8, 2026.

Haemonetics Corporation has released its financial results for the third quarter of FY2025, revealing trends in medical technology and investor insights.

Join Chris Simon, CEO of Haemonetics, as he addresses key healthcare advancements at the Bank of America 2026 Healthcare Conference.

Haemonetics has showcased a recent study highlighting the efficacy of its VASCADE MVP® XL system, emphasizing its safety in large-bore venous closure procedures during electrophysiology.

Boston-headquartered medical device group Haemonetics agrees to pay €100m upfront for Enterprise Ireland-backed company

Ils déplorent les conditions de travail et le manque de soutien de l'entreprise OpSens/Haemonetics à Québec.

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Haemonetics Corporation is one of them. Haemonetics Corporation (NYSE:HAE), a global leader in blood and plasma management technologies, continues to advance healthcare efficiency through innovative medical devices. In 2025, the company launched the PerQseal Elite […]

Ils déplorent les conditions de travail et le manque de soutien de l'entreprise OpSens/Haemonetics à Québec.

A multicenter study highlighted in Anesthesiology Journals clinically validated our TEG® 6s Global Hemostasis – HN cartridge by demonstrating high correlation with established assays in heparinized pa...

Galway medtech group was acquired in January by New York-listed Haemonetics in a deal worth up to €185m

Apheresis Market projected to grow at 6.86% CAGR, reaching USD 5.2 Billion by 2035, driving growth global trends, competitive industry analysis and outlook 2025-2035

Haemonetics received a fresh analyst action dated 2026-09-17.

Reported Thursday, Sep 17 - 5:17am EDT (TheFly subscription required to read more.)

Reported Thursday, Sep 17 - 5:40am EDT (TheFly subscription required to read more.)

Orchestra BioMed (OBIO) received a $6.1 million milestone payment on September 14, 2026, tied to Haemonetics’ acquisition of Vivasure Medical. This follows an approximately $5 million upfront payment in January 2026, bringing total cash proceeds from the transaction in 2026 to approximately $11 million, which completes the amount previously expected for this year.The company remains eligible for up to approximately $10 million in additional revenue-based earnout payments, for total potential proceeds of up to $21 million. Vivasure had been a strategic holding of Orchestra BioMed since the company’s formation. Management states that monetizing this holding provides incremental capital to advance its pivotal programs, including AVIM Therapy for uncontrolled hypertension and the Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease.

Tijuana.- El presidente municipal de Tijuana, Abdiel Gutiérrez Coronado, realizó una visita a Haemonetics, empresa global de tecnología médica instalada en Tijuana, donde hizo entrega del distintivo ACORDE (Acompañamiento y Cumplimiento para el Desarrollo Empresarial), como parte de las acciones del Gobierno Municipal para fortalecer la vinculación con el sector industrial. En este sentido, el alcalde Abdiel Gutiérrez Coronado, destacó ante los directivos de la empresa, la importancia de generar condiciones que favorezcan la permanencia, crecimiento y expansión de las empresas en la ciudad.

Reported Thursday, Sep 3 - 8:41am EDT (TheFly subscription required to read more.)

Haemonetics (NYSE: HAE) has recently received a number of price target changes and ratings updates: 8/21/2026 – Haemonetics had its price target raised by Robert W. Baird from $96.00 to $119.00. They now have an “outperform” rating on the stock. 8/19/2026 – Haemonetics had its price target raised by Barrington Research from $95.00 to $118.00. [...]